)
Therapeutic Areas and Products
Allergy and Immunology
Our world-leading immunoglobulin (Ig) franchise is the cornerstone of the immunology therapeutic area. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a range of rare and serious diseases, including Primary Immunodeficiencies (PID) and Hereditary Angioedema (HAE).
Key Publications
Efficacy and Safety of a new 20% Immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with Primary Immunodeficiency
Hagan, JB et al
J Clin Immunol
Request | Ask a Question
Efficacy and safety of Hizentra in patients with Primary Immunodeficiency after a dose-equivalent switch from IV or SC replacement therapy
Jolles, S et al
Clinical Immunology, 2011
Request | Ask a Question
Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with Primary Immunodeficiency Diseases
Kanegane, H et al
J Clin Immunol, 2013
Request | Ask a Question
Long-Term efficacy, safety and tolerability of Hizentra for treatment of Primary Immunodeficiency Disease
Jolles, S et al
Clinical Immunology, 2013
Request | Ask a Question